These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

791 related articles for article (PubMed ID: 28559413)

  • 21. An overview of triple negative breast cancer for surgical oncologists.
    Sharma S; Barry M; Gallagher DJ; Kell M; Sacchini V
    Surg Oncol; 2015 Sep; 24(3):276-83. PubMed ID: 26092709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Directed therapy of subtypes of triple-negative breast cancer.
    Carey LA
    Oncologist; 2011; 16 Suppl 1():71-8. PubMed ID: 21278443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted therapy for triple-negative breast cancer: where are we?
    Duffy MJ; McGowan PM; Crown J
    Int J Cancer; 2012 Dec; 131(11):2471-7. PubMed ID: 22581656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A targetable androgen receptor-positive breast cancer subtype hidden among the triple-negative cancers.
    Safarpour D; Tavassoli FA
    Arch Pathol Lab Med; 2015 May; 139(5):612-7. PubMed ID: 25310144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer.
    Cabezón T; Gromova I; Gromov P; Serizawa R; Timmermans Wielenga V; Kroman N; Celis JE; Moreira JM
    Mol Cell Proteomics; 2013 Feb; 12(2):381-94. PubMed ID: 23172894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting.
    Williams CB; Soloff AC; Ethier SP; Yeh ES
    Adv Cancer Res; 2015; 127():253-81. PubMed ID: 26093903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triple-negative breast cancers: Are they always different from nontriple-negative breast cancers? An experience from a tertiary center in India.
    ; Parshad R; Kazi M; Seenu V; Mathur S; Dattagupta S; Haresh KP
    Indian J Cancer; 2017; 54(4):658-663. PubMed ID: 30082553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
    Choi JE; Kang SH; Lee SJ; Bae YK
    Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tackling the diversity of triple-negative breast cancer.
    Turner NC; Reis-Filho JS
    Clin Cancer Res; 2013 Dec; 19(23):6380-8. PubMed ID: 24298068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Triple-negative breast cancer: is there a treatment on the horizon?
    Yao H; He G; Yan S; Chen C; Song L; Rosol TJ; Deng X
    Oncotarget; 2017 Jan; 8(1):1913-1924. PubMed ID: 27765921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mammographic density in relation to tumor biomarkers, molecular subtypes, and mode of detection in breast cancer.
    Sartor H; Zackrisson S; Elebro K; Hartman L; Borgquist S
    Cancer Causes Control; 2015 Jun; 26(6):931-9. PubMed ID: 25860114
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comprehensive profiling of biological processes reveals two major prognostic subtypes in breast cancer.
    Chen F; Gao S; Wang F; Ma J; Zhang M; Lv M; Zhou Q; Fu Z; Lu C; Yin H
    Tumour Biol; 2016 Mar; 37(3):3365-70. PubMed ID: 26446459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biomarkers of DNA Repair and Related Pathways: Significance of Treatment in Triple-Negative Breast Cancer.
    Guo W; Lin L; He X; He F; Wang C; Chen N; Wang Y
    Crit Rev Oncog; 2017; 22(5-6):427-437. PubMed ID: 29604922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of the androgen receptor in triple-negative breast cancer.
    Rampurwala M; Wisinski KB; O'Regan R
    Clin Adv Hematol Oncol; 2016 Mar; 14(3):186-93. PubMed ID: 27058032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Challenging clinical scenarios: treatment of patients with triple-negative or basal-like metastatic breast cancer.
    Greenberg S; Rugo HS
    Clin Breast Cancer; 2010 Sep; 10 Suppl 2():S20-9. PubMed ID: 20805062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The evolving management of metastatic triple negative breast cancer.
    Malhotra MK; Emens LA
    Semin Oncol; 2020 Aug; 47(4):229-237. PubMed ID: 32563561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Triple-negative breast cancer: histoclinical and molecular features, therapeutic management and perspectives].
    Gonçalves A; Sabatier R; Charafe-Jauffret E; Gilabert M; Provansal M; Tarpin C; Extra JM; Viens P; Bertucci F
    Bull Cancer; 2013 May; 100(5):453-64. PubMed ID: 23695030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microsatellite instability in Japanese female patients with triple-negative breast cancer.
    Kurata K; Kubo M; Kai M; Mori H; Kawaji H; Kaneshiro K; Yamada M; Nishimura R; Osako T; Arima N; Okido M; Oda Y; Nakamura M
    Breast Cancer; 2020 May; 27(3):490-498. PubMed ID: 31907878
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis.
    Stover DG; Coloff JL; Barry WT; Brugge JS; Winer EP; Selfors LM
    Clin Cancer Res; 2016 Dec; 22(24):6039-6050. PubMed ID: 27330058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features.
    Venkitaraman R
    Expert Rev Anticancer Ther; 2010 Feb; 10(2):199-207. PubMed ID: 20131996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.